基于PLGA的草药图森达宁输送系统,用于有效治疗口腔状细胞癌
Lingling Chen1, Cheng Feng1, Zhenyu Shi1
1Fujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
BMC complementary medicine and therapies
|July 3, 2025
概括
带有托桑达宁的多 (乳糖-同-甘油酸) 纳米颗粒 (TSN-PLGA NPs) 对口腔状细胞癌 (OSCC) 治疗有希望. 这些纳米粒子改善药物输送,在体外和体内表现出抗癌作用,并显示出良好的生物相容性.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 口腔状细胞癌 (OSCC) 是一个全球性的健康挑战,常规治疗选择有限.
- 天然化合物图森丹尼 (TSN) 已显示出抗癌潜力,但具有较差的溶解性和生物可用性.
- 开发新的药物输送系统对于提高TSN在OSCC中的治疗效果至关重要.
研究的目的:
- 开发和表征托森达宁载荷的多 (乳糖-co-糖酸) 纳米颗粒 (TSN-PLGA NPs) 以改善OSCC治疗.
- 评估TSN-PLGANP的体外和体内疗效和生物相容性.
主要方法:
- 合成了TSN-PLGANP,并以持续释放等特性进行了表征.
- 在体外研究中评估了OSCC细胞中的细胞毒性,增殖抑制,亡诱导和细胞循环停止.
- 通过RNA测序确定了受TSN-PLGANP影响的关键信号通路 (JAK/STAT,PI3K-Akt).
- 在裸体小鼠模型中评估了体内抗瘤活性和生物相容性.
主要成果:
- TSN-PLGA NPs在体外表现出持续的TSN释放.
- TSN-PLGA NPs对OSCC细胞表现出显著的细胞毒性作用,诱导S相停止.
- RNA-seq分析表明JAK/STAT和PI3K-Akt通路的调节.
- 在体内研究证实了TSN-PLGANP的抗瘤活性,在小鼠中没有观察到副作用.
结论:
- TSN-PLGA NPs有效地提高了TSN的可溶性和生物可用性,用于潜在的OSCC治疗.
- 这些纳米粒子在体外和体外显示出有希望的抗瘤功效和良好的生物相容性.
- TSN-PLGA NPs代表了口腔状细胞癌治疗的潜在新型化疗候选人.
相关概念视频
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


